CD59 glycoprotein (CD59) (CD59)

Protectin, canonically known as CD59 glycoprotein, is a vital membrane-bound regulator of the innate immune system. It is a small, glycosylphosphatidylinositol (GPI)-anchored protein expressed on the surface of nearly all human cells and tissues. Its primary biological function is to inhibit the terminal stage of the complement cascade by binding to the C8 and C9 components, thereby preventing the assembly and insertion of the membrane attack complex (MAC) into host cell membranes. By inhibiting pore formation, Protectin shields healthy cells from accidental immune-mediated lysis and damage. In clinical pathology, a deficiency or absence of Protectin is a defining characteristic of Paroxysmal Nocturnal Hemoglobinuria (PNH), where the loss of this protective shield leads to chronic intravascular hemolysis and thrombosis. Conversely, in the field of oncology, many tumor cells overexpress Protectin as a mechanism to evade complement-dependent cytotoxicity (CDC) induced by therapeutic monoclonal antibodies. Consequently, Protectin has emerged as a significant therapeutic target; researchers are developing inhibitors such as the peptide CP-06 and recombinant bacterial toxin domains like rILYd4 to sensitize cancer cells to immune attack. Additionally, recombinant soluble forms of Protectin and CD59-mimetic fusion proteins are being explored as treatments to mitigate tissue damage in complement-mediated inflammatory and autoimmune conditions.

Other names

ProtectinMembrane inhibitor of reactive lysisMIRLMAC-inhibitory proteinMAC-IPHomologous restriction factor 20HRF20P-181F5 antigenMEM-43 antigen

Targeted therapeutic agents act by either inhibiting CD59 to sensitize tumor cells to complement-dependent cytotoxicity (CDC) or by supplementing/mimicking CD59 activity to protect host tissues from unregulated complement-mediated lysis.